분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-15 14:13:56 , Hit : 1187
 AbbVie, Enanta drug shows potential in hep C genotype 4 patients


Tue Nov 11, 2014 10:28am EST

Mon, Nov 10 2014
RPT - INSIGHT-After hep C cure, companies target next big liver disease market
Mon, Nov 10 2014Analysis & OpinionSurprising source offers signs the global ‘war on drugs’ may be ending
Amgen boss makes a prime breakup target
Related TopicsHealth »
(Reuters) - AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.

The company is developing the drug with Enanta Pharmaceuticals Inc.

AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

Genotype 4 variant of the hepatitis C virus is more frequent in the Middle East and Africa, affecting about 34 million people across the world.

Other drugmakers such as Merck & Co Inc, Gilead Sciences Inc and Achillion Pharmaceuticals Inc have been working on their own hepatitis C candidates with the aim of reducing treatment time from the current 8-12 weeks.

J.P. Morgan Securities analysts said in a note that AbbVie's treatment duration is unlikely to move into the four-six week range.

However, they continue to expect AbbVie to capture at least 20 percent of the $15-billion-plus hepatitis C market next year.

AbbVie also presented data from another mid-stage study where patients infected with both genotype 1 hepatitis C and HIV viruses showed response rates of 93.5 percent and 90.6 percent after 12 and 24 weeks post-treatment, respectively.

AbbVie's treatments are co-administered with Ribavirin, a commonly used drug in the treatment of hepatitis C which comes with a harsh safety profile.

Shares of AbbVie were up 0.11 percent at $63.72 and those of Enanta were down 0.20 percent at $44.05 in early trading.


(Reporting by Amrutha Penumudi in Bangalore)







827   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1669
826   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1077
825   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1240
824   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1095
823   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1144
822   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1722
821   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1344
820   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1272
819   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1617
818   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1284
817   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1394
816   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1924
815   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1129
814   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1494
813   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1162
812   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1602
811   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1665
  AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1187
809   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1068
808   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1472

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN